ArticleNeurological research and practice2021

Evidence of extensive cellular immune response after SARS-CoV-2 vaccination in ocrelizumab-treated patients with multiple sclerosis.

Mosche Pompsch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.